Author

G. Georgiopoulos

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Cardiovascular and economic outcomes of combined liraglutide and empagliflozin therapy in type 2 diabetes: a 6-year study

Type 2 Diabetes Mellitus (T2DM) yields high cardiovascular morbidity, resulting in overwhelming healthcare costs. We investigated whether the combined administration of the cardioprotective agent Glucagon-Like Peptide-1 receptor agonists (GLP1-RA) liraglutide and Sodium-Glucose Cotransporter-2 Inhibitor (S...

J. Thymis, G. Oikonomidis, G. Georgiopoulos et al. · European Heart Journal · 0 citations

Open access Oct 2026

Prognostic value of CMR-derived right ventricular global longitudinal strain in light-chain cardiac amyloidosis

Cardiac involvement determines prognosis in light-chain (AL) amyloidosis. The incremental prognostic role of right ventricular (RV) deformation assessed by cardiac magnetic resonance (CMR) remains incompletely defined. In a prospective cohort of 100 patients with AL amyloidosis, baseline clinical, biomarke...

V. Mikros, N. Lama, F. Theodorakakou et al. · European Heart Journal · 0 citations

Open access Oct 2026

Dapagliflozin ameliorates arterial stiffness, endothelial glycocaclyx and myocardial performance in non-diabetic STEMI patients: a 3-month follow-up study

Sodium glucose Cotransporter-2 inhibitor (SGLT2i) have been recently administered efficiently in the acute phase of Acute Myocardial Infarctions (AMI) in patients without diabetes or heart failure. We aimed to address the effects of dapagliflozin in arterial wall elastic properties, thickness of endothelia...

J. Thymis, G. Georgiopoulos, K. Katogiannis et al. · European Heart Journal · 0 citations